Sanofi SA (SASY.PA)
24 Nov 2014
|Market Cap (Mil.):||€99,549.70|
|Shares Outstanding (Mil.):||1,326.97|
* Zealand informs that Sanofi has confirmed development plans for LixiLan at Investor Relations Thematic Seminar
PARIS, Nov 20 - Sanofi Chairman Serge Weinberg to reporters on a conference call on Thursday:
PARIS - Sanofi, which sacked its chief executive three weeks ago, gave a weak sales outlook for its diabetes drugs on Thursday, overshadowing plans to reap more than 30 billion euros ($38 billion) from new medicines.
* Sees up to six new drug launches in 2015, 18 by end-2020
PARIS, Nov 20 - Sanofi and its U.S. partner Regeneron said on Thursday the U.S. Food and Drug Administration had designated their dupilumab drug as "breakthrough therapy" in the treatment of atopic dermatitis, a chronic form of eczema, granting the product a fast-track development and review process.
PARIS, Nov 20 - Sanofi set out its strategy for bringing several new drugs to the market on Thursday, in a bid to win over investors alarmed by the sudden ouster of its chief executive and problems in the field of diabetes.
* Fourtou to lead appointments and governance committee -source
PARIS, Nov 18 - Sanofi is drawing up a shortlist of candidates for the post of chief executive to replace Chris Viehbacher, ousted by the board last month, a source close to the French drugmaker told Reuters.
PARIS, Nov 18 - Sanofi said on Tuesday it had nominated Bonnie Bassler, a molecular biology professor, as an independent member of its board of directors.
PARIS, Nov 17 - Sanofi will hold a board meeting by telephone on Tuesday from 1100 GMT to 1200 GMT, according to two sources close to the French drugmaker.